AR043251A1 - Formulaciones de esteroides para tratar personas que sufren de transtornos oculares - Google Patents

Formulaciones de esteroides para tratar personas que sufren de transtornos oculares

Info

Publication number
AR043251A1
AR043251A1 ARP040100544A ARP040100544A AR043251A1 AR 043251 A1 AR043251 A1 AR 043251A1 AR P040100544 A ARP040100544 A AR P040100544A AR P040100544 A ARP040100544 A AR P040100544A AR 043251 A1 AR043251 A1 AR 043251A1
Authority
AR
Argentina
Prior art keywords
phenyl
triazol
thio
ethanone
pyridin
Prior art date
Application number
ARP040100544A
Other languages
English (en)
Spanish (es)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR043251A1 publication Critical patent/AR043251A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ARP040100544A 2003-02-20 2004-02-20 Formulaciones de esteroides para tratar personas que sufren de transtornos oculares AR043251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44894303P 2003-02-20 2003-02-20

Publications (1)

Publication Number Publication Date
AR043251A1 true AR043251A1 (es) 2005-07-20

Family

ID=32908674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100544A AR043251A1 (es) 2003-02-20 2004-02-20 Formulaciones de esteroides para tratar personas que sufren de transtornos oculares

Country Status (16)

Country Link
US (2) US20040171598A1 (https=)
EP (1) EP1670480A4 (https=)
JP (1) JP2006518382A (https=)
KR (1) KR20050102652A (https=)
CN (1) CN1750828A (https=)
AR (1) AR043251A1 (https=)
AU (1) AU2004212895A1 (https=)
BR (1) BRPI0407693A (https=)
CA (1) CA2516782A1 (https=)
MX (1) MXPA05008561A (https=)
PL (1) PL378210A1 (https=)
RU (1) RU2005129276A (https=)
TW (1) TW200511996A (https=)
UY (1) UY28202A1 (https=)
WO (1) WO2004073607A2 (https=)
ZA (1) ZA200505989B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
SI1755616T1 (sl) * 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
KR101430760B1 (ko) 2005-10-18 2014-08-19 알러간, 인코포레이티드 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
ITRM20050547A1 (it) * 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
EP2262506B1 (en) 2008-03-11 2014-05-07 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
EP2977084B1 (en) * 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
KR101106074B1 (ko) * 2011-05-27 2012-01-18 김선미 교통 시설물 설치용 부착대 및 지주장치
EP3148525B1 (en) 2014-05-30 2023-10-11 Aarhus Universitet Cafestol for treating diabetes
HK1249460A1 (zh) 2015-03-06 2018-11-02 Aerie Pharmaceuticals, Inc. 植入物施用器和植入物的施用方法
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
WO2019060696A1 (en) * 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
PT1221918E (pt) * 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
IL180679A0 (en) * 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same

Also Published As

Publication number Publication date
PL378210A1 (pl) 2006-03-20
WO2004073607A3 (en) 2004-11-25
CN1750828A (zh) 2006-03-22
EP1670480A4 (en) 2007-10-10
EP1670480A2 (en) 2006-06-21
WO2004073607A2 (en) 2004-09-02
US20060154910A1 (en) 2006-07-13
MXPA05008561A (es) 2005-11-04
ZA200505989B (en) 2006-12-27
AU2004212895A1 (en) 2004-09-02
CA2516782A1 (en) 2004-09-02
KR20050102652A (ko) 2005-10-26
UY28202A1 (es) 2004-08-31
RU2005129276A (ru) 2006-01-27
US20040171598A1 (en) 2004-09-02
JP2006518382A (ja) 2006-08-10
TW200511996A (en) 2005-04-01
BRPI0407693A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
AR043251A1 (es) Formulaciones de esteroides para tratar personas que sufren de transtornos oculares
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE602006017261D1 (de) Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen
UY24543A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol- 3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
NO971471L (no) Nye karboksamider med fungicid aktivitet
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
RU2008145225A (ru) Соединения индазола и способы ингибирования cd7
BRPI0502557A (pt) composição microbicida, e, método para tratar água
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
EA200900913A1 (ru) Производное триазола в качестве ингибитора hsp90
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
TW200736255A (en) 5-(Substituted)-pyrazolopiperidines
PE20060362A1 (es) Compuestos de oxazol como moduladores de ppar
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
EP1393747A4 (en) AGENT FOR PREVENTION / TREATMENT OF ALZHEIMER DISEASE
AR043250A1 (es) Derivados de triazol como agentes insecticidas y antihelminticos
NO20043585L (no) Behandling av reumatoid artritt

Legal Events

Date Code Title Description
FA Abandonment or withdrawal